Epigenetic modulation of vascular diseases: Assessing the evidence and exploring  the opportunities

dc.contributor.author	Schiattarella GG
dc.contributor.author	Madonna R
dc.contributor.author	Van Linthout S
dc.contributor.author	Thum T
dc.contributor.author	Schulz R
dc.contributor.author	Ferdinandy, Péter
dc.contributor.author	Perrino C
dc.date.accessioned	2018-08-30T09:34:59Z
dc.date.available	2018-08-30T09:34:59Z
dc.date.issued	2018
dc.identifier.citation	pagination=43-52; journalVolume=107; journalTitle=VASCULAR PHARMACOLOGY;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/6221
dc.identifier.uri	doi:10.1016/j.vph.2018.02.009
dc.description.abstract	Vascular adaptations to either physiological or pathophysiological conditions commonly require gene expression modifications in the most represented cellular elements of the vessel wall, i.e. endothelial and smooth muscle cells. In addition to transcription factors, a number of mechanisms contribute to the regulation of gene expression in these cells including noncoding RNAs, histone and DNA modifications, collectively indicated as epigenetic modifications. Here, we summarize the state of art regarding the role of epigenetic changes in major vascular diseases, and discuss the potential diagnostic and therapeutic applications of epigenetic modulation in this context.
dc.relation.ispartof	urn:issn:1537-1891
dc.title	Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities
dc.type	Journal Article
dc.date.updated	2018-08-28T18:15:13Z
dc.language.rfc3066	en
dc.identifier.mtmt	3352001
dc.identifier.pubmed	29548901
dc.contributor.department	SE/AOK/I/Farmakológiai és Farmakoterápiás Intézet
dc.contributor.institution	Semmelweis Egyetem